3PE-33153-77816
1 vaccination
1 coded response
8 check-ins
1 free-text entry
1 call case
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 351 / AL
- Registered
- 2021-03-14
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-03-13
Dose 1 — Pfizer-BioNTech
-
2021-03-14
Registered in v-safe
- 2021-03-14
-
2021-03-15
Health check-in — days 1–6 daily, dose 1Feeling: Fair · Muscle or body aches, Fatigue or tirednessAdult check-in
- 2021-03-17
- 2021-03-18
- 2021-03-19
- 2021-03-22
- 2021-09-11
- 2022-03-05
-
2022-03-13
Survey response — 12 months, dose 1MedDRA: Dizziness — Feeling: Good · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: DizzinessMedDRA releases: 2024-11 · check-in free text available
-
2022-03-13
Report sent to call center — 12 months, dose 1Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-03-13 | Pfizer-BioNTech |
Call center
| Reported | Outcome | VAERS-related outcome |
|---|---|---|
| 2022-03-13 | Unsuccessful |
Free text
Release 11 — 12 months, dose 1
Symptoms: Dizziness
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Dizziness | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release